Latest News

Aug 15, 2017
Lytix Biopharma completes 1st cohort of LTX-315 monotherapy
Jul 3, 2017
2nd combination cohort of LTX-315 and pembrolizumab in TNBC completed
Jun 6, 2017
HalioDx SAS, an immuno-oncology diagnostic company, presented Phase I data on LTX-315 at ASCO
Jun 5, 2017
ASCO 2017 - Lytix Biopharma featured in Dagens Medisin

Meet the Management Team